市場調査レポート

商品コード

1603762

ヘパリンカルシウムの世界市場予測（～2030年）：製品、流通チャネル、用途、地域別の分析

Heparin Calcium Market Forecasts to 2030 - Global Analysis By Product (Unfractionated Heparin, Low Molecular Weight Heparin (LMWH) and Other Products), Distribution Channel, Application and By Geography

出版日: 2024年11月11日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 610,008円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 771,697円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 933,386円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,102,425円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のヘパリンカルシウムの市場規模は、2024年に15億279万米ドルを占め、予測期間中のCAGRは4.7%で、2030年には19億7,961万米ドルに達すると予測されています。

ヘパリンカルシウムは抗凝固剤ヘパリンの一種で、体内に天然に存在する物質であり、カルシウムイオンとの複合体です。深部静脈血栓症、肺塞栓症、手術中や透析中など、さまざまな症状における血栓の予防や治療に医療的に使用されます。ヘパリンカルシウムは、血液凝固因子を阻害することにより、血栓の形成を抑制します。ヘパリンカルシウムは注射または点滴で投与され、出血性合併症の危険性があるため、投与量は慎重に管理されます。

MDPIジャーナルに掲載されたデータによると、ヘパリンは凝固時間を延長させる抗凝固剤として広く使用されています。

心血管疾患の増加

深部静脈血栓症（DVT）、肺塞栓症、心房細動などの心血管疾患では、血栓を予防し、脳卒中や心臓発作のリスクを低下させるために、抗凝固療法が頻繁に必要となります。広く使用されている抗凝固剤ヘパリンカルシウムは、血栓形成を防ぐことにより、多くの疾患の治療に不可欠です。高齢化、生活習慣の乱れ、肥満率の上昇などの要因により、CVDの有病率が世界的に上昇するにつれ、ヘパリンカルシウム療法に対する需要は増加します。病院、診療所、その他の医療専門家が、心血管疾患に関連する血液凝固問題を治療するために信頼できる抗凝固薬を探しているため、この動向が市場拡大を後押ししています。

副作用と合併症

打撲、出血、血小板減少症などの一般的な副作用は、特にすでに医学的問題を抱えている人に大きな健康被害をもたらし、使用を制限する可能性があります。また、身体の免疫系が血小板を破壊する疾患であるヘパリン誘発性血小板減少症（HIT）を発症している場合には、致命的な結果を招くこともあります。このような問題の結果、治療費と患者のコンプライアンスが上昇する可能性があり、綿密な観察と投与量の変更が頻繁に必要となります。外科医は好ましくない反応を懸念して、副作用の少ない最近の抗凝固薬を処方することがあります。その結果、ヘパリンカルシウムに関連する可能性のある危険性は、医療専門家や患者の間で消極的な姿勢を誘発し、一般的に市場の需要にマイナスの影響を与えます。

研究開発

研究開発の進歩は、より安全で、より効果的で、患者にとってより嗜好性の高いヘパリンカルシウム製品の創出につながります。研究開発努力はまた、がん関連血栓症のような多くの病気への適用を増やすために、ヘパリンの安定性とバイオアベイラビリティを高めることに集中しています。さらに、個別化医療と併用療法の継続的な研究により、ヘパリンカルシウム治療の有効性が向上し、治療適応が拡大する可能性があります。したがって、治療効果を向上させ、既存の医療市場と新規医療市場の両方での使用を後押しすることで、研究開発は市場の成長を促進します。

汚染のリスク

粗悪な製造慣行や不純物の混入した原材料に起因する汚染は、アレルギー反応、重篤な出血、あるいは死亡事故といった有害な副作用を引き起こす可能性があります。このような事故は、規制当局の監督強化を余儀なくさせ、製品の承認を遅らせ、製造コストを上昇させます。さらに、安全性に対する消費者の懸念が高まると、医療提供者はヘパリンカルシウムの処方を控えるようになり、市場の需要と成長の可能性が減少することになります。これらの事象は、規制当局の監視の強化や品質管理の厳格化につながり、製造コストを増加させ、市場における安全で効果的なヘパリンカルシウム製品の利用可能性を制限します。

COVID-19の影響

COVID-19の大流行はヘパリンカルシウム市場に大きな影響を与えました。COVID-19の重症患者では血液凝固のリスクが高まるため、抗凝固剤の需要が急増したからです。病院や医療提供者はヘパリンの調達を優先し、サプライチェーンの混乱と生産努力の増加につながりました。しかし、パンデミックは製造・流通網を緊張させ、その結果、時折欠品が発生しました。パンデミックが沈静化するにつれ、ヘパリンカルシウムの需要は安定すると予想されますが、クリティカルケアにおけるヘパリンの役割は依然として極めて重要です。

予測期間中、薬局セグメントが最大となる見込み

薬局セグメントは、この重要な抗凝固剤の入手しやすさと流通の増加により、有利な成長を遂げると推定されます。大手薬局チェーンがその範囲を拡大するにつれて、特に患者の需要が高い地域でヘパリンカルシウムの広範な入手可能性が確保されます。これらの薬局は、ヘパリンカルシウムを医療提供者や患者が容易に入手できるようにする上で極めて重要な役割を果たしており、販売量の増加を促進しています。さらに、大規模な薬局は大量購入と流通を処理するインフラを持っていることが多く、安定した供給を保証することで市場の成長を支えています。患者や医療従事者の教育における影響力が、臨床現場におけるヘパリンカルシウムの需要をさらに押し上げています。

診断薬セグメントは予測期間中に最も高いCAGRが見込まれる

様々な診断および医療処置、特に血液凝固検査におけるこの抗凝固剤の需要により、診断セグメントは予測期間中に最も高いCAGRの成長が見込まれます。ヘパリンカルシウムは、サンプル採取時の血液凝固を防ぎ、正確な結果を得るために、ラボ検査でよく使用されます。血小板凝集検査やトロンビン生成検査などの診断手順におけるヘパリンカルシウムの役割は、血液凝固障害を検出するために極めて重要です。診断技術の進歩に伴い、ヘパリンカルシウムのような高品質で信頼性の高い抗凝固剤のニーズが高まり、医療診断における用途がさらに拡大し、市場の成長に寄与しています。

最大のシェアを占める地域

アジア太平洋は、心血管疾患の有病率の上昇、外科手術の増加、高齢化により、予測期間中に最大の市場シェアを占めると予測されます。中国、インド、日本などの国々が主要な貢献国であり、医療インフラの拡大と治療へのアクセスの向上が需要を促進しています。さらにこの市場は、特に医療投資が増加し抗凝固剤の必要性が高まっている新興国において、大きなビジネスチャンスをもたらしています。

CAGRが最も高い地域：

高齢化の進展により、予測期間中のCAGRは北米が最も高いと予測されます。米国とカナダは、強固な医療システムを有し、抗凝固療法の需要が高いことが主な要因です。さらに、大手製薬会社の存在と医学研究の進歩も市場の成長に寄与しています。しかし、より利便性の高い新規抗凝固薬との競合や、ヘパリンカルシウムの潜在的な副作用が課題となる可能性があります。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東・アフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品発売
事業拡大
その他の主要戦略

第10章企業プロファイリング

Pfizer Inc.
Sanofi S.A.
B. Braun Melsungen AG
Baxter International Inc.
Leo Pharma A/S
Fresenius SE & Co. KGaA
Teva Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals PLC
Aspen Pharmacare Holdings Limited
Sagent Pharmaceuticals, Inc.
Syntex S.A.
Daiichi Sankyo Company, Limited
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
Bioiberica S.A.U.
Xinbai Pharmaceuticals Co., Ltd.
Laboratorios Rovi, S.A.
Techdow Pharma
Opocrin S.p.A.

図表

List of Tables

Table 1 Global Heparin Calcium Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Heparin Calcium Market Outlook, By Product (2022-2030) ($MN)
Table 3 Global Heparin Calcium Market Outlook, By Unfractionated Heparin (2022-2030) ($MN)
Table 4 Global Heparin Calcium Market Outlook, By Low Molecular Weight Heparin (LMWH) (2022-2030) ($MN)
Table 5 Global Heparin Calcium Market Outlook, By Other Products (2022-2030) ($MN)
Table 6 Global Heparin Calcium Market Outlook, By Distribution Channel (2022-2030) ($MN)
Table 7 Global Heparin Calcium Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
Table 8 Global Heparin Calcium Market Outlook, By Pharmacies (2022-2030) ($MN)
Table 9 Global Heparin Calcium Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
Table 10 Global Heparin Calcium Market Outlook, By Application (2022-2030) ($MN)
Table 11 Global Heparin Calcium Market Outlook, By Therapeutic Applications (2022-2030) ($MN)
Table 12 Global Heparin Calcium Market Outlook, By Deep Vein Thrombosis (DVT) (2022-2030) ($MN)
Table 13 Global Heparin Calcium Market Outlook, By Pulmonary Embolism (PE) (2022-2030) ($MN)
Table 14 Global Heparin Calcium Market Outlook, By Myocardial Infarction (MI) (2022-2030) ($MN)
Table 15 Global Heparin Calcium Market Outlook, By Atrial Fibrillation (AFib) (2022-2030) ($MN)
Table 16 Global Heparin Calcium Market Outlook, By Surgical Procedures (2022-2030) ($MN)
Table 17 Global Heparin Calcium Market Outlook, By Cardiovascular Surgery (2022-2030) ($MN)
Table 18 Global Heparin Calcium Market Outlook, By Orthopedic Surgery (2022-2030) ($MN)
Table 19 Global Heparin Calcium Market Outlook, By General Surgery (2022-2030) ($MN)
Table 20 Global Heparin Calcium Market Outlook, By Diagnostics (2022-2030) ($MN)
Table 21 Global Heparin Calcium Market Outlook, By Other Applications (2022-2030) ($MN)
Table 22 North America Heparin Calcium Market Outlook, By Country (2022-2030) ($MN)
Table 23 North America Heparin Calcium Market Outlook, By Product (2022-2030) ($MN)
Table 24 North America Heparin Calcium Market Outlook, By Unfractionated Heparin (2022-2030) ($MN)
Table 25 North America Heparin Calcium Market Outlook, By Low Molecular Weight Heparin (LMWH) (2022-2030) ($MN)
Table 26 North America Heparin Calcium Market Outlook, By Other Products (2022-2030) ($MN)
Table 27 North America Heparin Calcium Market Outlook, By Distribution Channel (2022-2030) ($MN)
Table 28 North America Heparin Calcium Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
Table 29 North America Heparin Calcium Market Outlook, By Pharmacies (2022-2030) ($MN)
Table 30 North America Heparin Calcium Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
Table 31 North America Heparin Calcium Market Outlook, By Application (2022-2030) ($MN)
Table 32 North America Heparin Calcium Market Outlook, By Therapeutic Applications (2022-2030) ($MN)
Table 33 North America Heparin Calcium Market Outlook, By Deep Vein Thrombosis (DVT) (2022-2030) ($MN)
Table 34 North America Heparin Calcium Market Outlook, By Pulmonary Embolism (PE) (2022-2030) ($MN)
Table 35 North America Heparin Calcium Market Outlook, By Myocardial Infarction (MI) (2022-2030) ($MN)
Table 36 North America Heparin Calcium Market Outlook, By Atrial Fibrillation (AFib) (2022-2030) ($MN)
Table 37 North America Heparin Calcium Market Outlook, By Surgical Procedures (2022-2030) ($MN)
Table 38 North America Heparin Calcium Market Outlook, By Cardiovascular Surgery (2022-2030) ($MN)
Table 39 North America Heparin Calcium Market Outlook, By Orthopedic Surgery (2022-2030) ($MN)
Table 40 North America Heparin Calcium Market Outlook, By General Surgery (2022-2030) ($MN)
Table 41 North America Heparin Calcium Market Outlook, By Diagnostics (2022-2030) ($MN)
Table 42 North America Heparin Calcium Market Outlook, By Other Applications (2022-2030) ($MN)
Table 43 Europe Heparin Calcium Market Outlook, By Country (2022-2030) ($MN)
Table 44 Europe Heparin Calcium Market Outlook, By Product (2022-2030) ($MN)
Table 45 Europe Heparin Calcium Market Outlook, By Unfractionated Heparin (2022-2030) ($MN)
Table 46 Europe Heparin Calcium Market Outlook, By Low Molecular Weight Heparin (LMWH) (2022-2030) ($MN)
Table 47 Europe Heparin Calcium Market Outlook, By Other Products (2022-2030) ($MN)
Table 48 Europe Heparin Calcium Market Outlook, By Distribution Channel (2022-2030) ($MN)
Table 49 Europe Heparin Calcium Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
Table 50 Europe Heparin Calcium Market Outlook, By Pharmacies (2022-2030) ($MN)
Table 51 Europe Heparin Calcium Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
Table 52 Europe Heparin Calcium Market Outlook, By Application (2022-2030) ($MN)
Table 53 Europe Heparin Calcium Market Outlook, By Therapeutic Applications (2022-2030) ($MN)
Table 54 Europe Heparin Calcium Market Outlook, By Deep Vein Thrombosis (DVT) (2022-2030) ($MN)
Table 55 Europe Heparin Calcium Market Outlook, By Pulmonary Embolism (PE) (2022-2030) ($MN)
Table 56 Europe Heparin Calcium Market Outlook, By Myocardial Infarction (MI) (2022-2030) ($MN)
Table 57 Europe Heparin Calcium Market Outlook, By Atrial Fibrillation (AFib) (2022-2030) ($MN)
Table 58 Europe Heparin Calcium Market Outlook, By Surgical Procedures (2022-2030) ($MN)
Table 59 Europe Heparin Calcium Market Outlook, By Cardiovascular Surgery (2022-2030) ($MN)
Table 60 Europe Heparin Calcium Market Outlook, By Orthopedic Surgery (2022-2030) ($MN)
Table 61 Europe Heparin Calcium Market Outlook, By General Surgery (2022-2030) ($MN)
Table 62 Europe Heparin Calcium Market Outlook, By Diagnostics (2022-2030) ($MN)
Table 63 Europe Heparin Calcium Market Outlook, By Other Applications (2022-2030) ($MN)
Table 64 Asia Pacific Heparin Calcium Market Outlook, By Country (2022-2030) ($MN)
Table 65 Asia Pacific Heparin Calcium Market Outlook, By Product (2022-2030) ($MN)
Table 66 Asia Pacific Heparin Calcium Market Outlook, By Unfractionated Heparin (2022-2030) ($MN)
Table 67 Asia Pacific Heparin Calcium Market Outlook, By Low Molecular Weight Heparin (LMWH) (2022-2030) ($MN)
Table 68 Asia Pacific Heparin Calcium Market Outlook, By Other Products (2022-2030) ($MN)
Table 69 Asia Pacific Heparin Calcium Market Outlook, By Distribution Channel (2022-2030) ($MN)
Table 70 Asia Pacific Heparin Calcium Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
Table 71 Asia Pacific Heparin Calcium Market Outlook, By Pharmacies (2022-2030) ($MN)
Table 72 Asia Pacific Heparin Calcium Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
Table 73 Asia Pacific Heparin Calcium Market Outlook, By Application (2022-2030) ($MN)
Table 74 Asia Pacific Heparin Calcium Market Outlook, By Therapeutic Applications (2022-2030) ($MN)
Table 75 Asia Pacific Heparin Calcium Market Outlook, By Deep Vein Thrombosis (DVT) (2022-2030) ($MN)
Table 76 Asia Pacific Heparin Calcium Market Outlook, By Pulmonary Embolism (PE) (2022-2030) ($MN)
Table 77 Asia Pacific Heparin Calcium Market Outlook, By Myocardial Infarction (MI) (2022-2030) ($MN)
Table 78 Asia Pacific Heparin Calcium Market Outlook, By Atrial Fibrillation (AFib) (2022-2030) ($MN)
Table 79 Asia Pacific Heparin Calcium Market Outlook, By Surgical Procedures (2022-2030) ($MN)
Table 80 Asia Pacific Heparin Calcium Market Outlook, By Cardiovascular Surgery (2022-2030) ($MN)
Table 81 Asia Pacific Heparin Calcium Market Outlook, By Orthopedic Surgery (2022-2030) ($MN)
Table 82 Asia Pacific Heparin Calcium Market Outlook, By General Surgery (2022-2030) ($MN)
Table 83 Asia Pacific Heparin Calcium Market Outlook, By Diagnostics (2022-2030) ($MN)
Table 84 Asia Pacific Heparin Calcium Market Outlook, By Other Applications (2022-2030) ($MN)
Table 85 South America Heparin Calcium Market Outlook, By Country (2022-2030) ($MN)
Table 86 South America Heparin Calcium Market Outlook, By Product (2022-2030) ($MN)
Table 87 South America Heparin Calcium Market Outlook, By Unfractionated Heparin (2022-2030) ($MN)
Table 88 South America Heparin Calcium Market Outlook, By Low Molecular Weight Heparin (LMWH) (2022-2030) ($MN)
Table 89 South America Heparin Calcium Market Outlook, By Other Products (2022-2030) ($MN)
Table 90 South America Heparin Calcium Market Outlook, By Distribution Channel (2022-2030) ($MN)
Table 91 South America Heparin Calcium Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
Table 92 South America Heparin Calcium Market Outlook, By Pharmacies (2022-2030) ($MN)
Table 93 South America Heparin Calcium Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
Table 94 South America Heparin Calcium Market Outlook, By Application (2022-2030) ($MN)
Table 95 South America Heparin Calcium Market Outlook, By Therapeutic Applications (2022-2030) ($MN)
Table 96 South America Heparin Calcium Market Outlook, By Deep Vein Thrombosis (DVT) (2022-2030) ($MN)
Table 97 South America Heparin Calcium Market Outlook, By Pulmonary Embolism (PE) (2022-2030) ($MN)
Table 98 South America Heparin Calcium Market Outlook, By Myocardial Infarction (MI) (2022-2030) ($MN)
Table 99 South America Heparin Calcium Market Outlook, By Atrial Fibrillation (AFib) (2022-2030) ($MN)
Table 100 South America Heparin Calcium Market Outlook, By Surgical Procedures (2022-2030) ($MN)
Table 101 South America Heparin Calcium Market Outlook, By Cardiovascular Surgery (2022-2030) ($MN)
Table 102 South America Heparin Calcium Market Outlook, By Orthopedic Surgery (2022-2030) ($MN)
Table 103 South America Heparin Calcium Market Outlook, By General Surgery (2022-2030) ($MN)
Table 104 South America Heparin Calcium Market Outlook, By Diagnostics (2022-2030) ($MN)
Table 105 South America Heparin Calcium Market Outlook, By Other Applications (2022-2030) ($MN)
Table 106 Middle East & Africa Heparin Calcium Market Outlook, By Country (2022-2030) ($MN)
Table 107 Middle East & Africa Heparin Calcium Market Outlook, By Product (2022-2030) ($MN)
Table 108 Middle East & Africa Heparin Calcium Market Outlook, By Unfractionated Heparin (2022-2030) ($MN)
Table 109 Middle East & Africa Heparin Calcium Market Outlook, By Low Molecular Weight Heparin (LMWH) (2022-2030) ($MN)
Table 110 Middle East & Africa Heparin Calcium Market Outlook, By Other Products (2022-2030) ($MN)
Table 111 Middle East & Africa Heparin Calcium Market Outlook, By Distribution Channel (2022-2030) ($MN)
Table 112 Middle East & Africa Heparin Calcium Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
Table 113 Middle East & Africa Heparin Calcium Market Outlook, By Pharmacies (2022-2030) ($MN)
Table 114 Middle East & Africa Heparin Calcium Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
Table 115 Middle East & Africa Heparin Calcium Market Outlook, By Application (2022-2030) ($MN)
Table 116 Middle East & Africa Heparin Calcium Market Outlook, By Therapeutic Applications (2022-2030) ($MN)
Table 117 Middle East & Africa Heparin Calcium Market Outlook, By Deep Vein Thrombosis (DVT) (2022-2030) ($MN)
Table 118 Middle East & Africa Heparin Calcium Market Outlook, By Pulmonary Embolism (PE) (2022-2030) ($MN)
Table 119 Middle East & Africa Heparin Calcium Market Outlook, By Myocardial Infarction (MI) (2022-2030) ($MN)
Table 120 Middle East & Africa Heparin Calcium Market Outlook, By Atrial Fibrillation (AFib) (2022-2030) ($MN)
Table 121 Middle East & Africa Heparin Calcium Market Outlook, By Surgical Procedures (2022-2030) ($MN)
Table 122 Middle East & Africa Heparin Calcium Market Outlook, By Cardiovascular Surgery (2022-2030) ($MN)
Table 123 Middle East & Africa Heparin Calcium Market Outlook, By Orthopedic Surgery (2022-2030) ($MN)
Table 124 Middle East & Africa Heparin Calcium Market Outlook, By General Surgery (2022-2030) ($MN)
Table 125 Middle East & Africa Heparin Calcium Market Outlook, By Diagnostics (2022-2030) ($MN)
Table 126 Middle East & Africa Heparin Calcium Market Outlook, By Other Applications (2022-2030) ($MN)

Product Code: SMRC27782

According to Stratistics MRC, the Global Heparin Calcium Market is accounted for $1502.79 million in 2024 and is expected to reach $1979.61 million by 2030 growing at a CAGR of 4.7% during the forecast period. Heparin calcium is a form of the anticoagulant heparin, a naturally occurring substance in the body, and complexes with calcium ions. It is used medically to prevent and treat blood clots in various conditions, such as deep vein thrombosis, pulmonary embolism, and during surgeries or dialysis. Heparin calcium works by inhibiting clotting factors, thereby reducing the formation of clots. It is administered via injection or intravenous infusion, and its dosage is carefully controlled due to the risk of bleeding complications.

According to data published in MDPI Journal, Heparin is a widely used anticoagulant substance that increases the clotting time.

Market Dynamics:

Driver:

Rising incidence of cardiovascular diseases

Anticoagulation therapy is frequently necessary for CVDs such deep vein thrombosis (DVT), pulmonary embolism, and atria fibrillation in order to prevent blood clots and lower the risk of stroke or heart attack. By preventing clot formation, the widely used anticoagulant heparin calcium is essential in the treatment of many disorders. The demand for heparin calcium therapy increases as the prevalence of CVDs rises globally as a result of factors like ageing populations, poor lifestyles, and rising obesity rates. As hospitals, clinics, and other healthcare professionals look for trustworthy anticoagulants to treat blood clotting issues linked to cardiovascular illnesses, this trend propels market expansion.

Restraint:

Side effects and complications

Common side effects, such as bruising, bleeding, and thrombocytopenia, can pose major health hazards and restrict its use, particularly in people who already have medical issues. It can also be fatal if you have heparin-induced thrombocytopenia (HIT), a disorder in which the body's immune system destroys platelets. Treatment expenses and patient compliance may rise as a result of these problems, which frequently call for close observation and dosage modifications. Surgeons may prescribe more recent anticoagulants with less side effects out of concern for unfavourable reactions. Consequently, the possible hazards linked to heparin calcium induce reluctance among medical professionals and patients, negatively impact market demand in general.

Opportunity:

Research and development

Research and development advancements result in the creation of heparin calcium products that are safer, more effective, and more palatable for patients. R&D efforts also concentrate on enhancing heparin's stability and bioavailability in order to increase its application in a number of illnesses, such as cancer-associated thrombosis. Additionally, continued research into personalised medicine and combination therapy may improve the effectiveness of heparin calcium treatments, expanding their therapeutic indications. Therefore, by enhancing treatment results and boosting usage in both established and new healthcare markets, R&D propels market growth.

Threat:

Risk of contamination

Contamination, often stemming from poor manufacturing practices or adulterated raw materials, can lead to harmful side effects like allergic reactions, severe bleeding, or even fatality. Such incidents force stricter regulatory oversight, delaying product approvals and increasing production costs. Additionally, heightened consumer concerns over safety may discourage healthcare providers from prescribing heparin calcium, leading to reduced demand and growth potential for the market. These events lead to heightened regulatory oversight and stricter quality control measures, increasing production costs and limiting the availability of safe, effective heparin calcium products in the market.

Covid-19 Impact

The COVID-19 pandemic had a significant impact on the Heparin Calcium market, as the demand for anticoagulants surged due to the increased risk of blood clotting in severe COVID-19 patients. Hospitals and healthcare providers prioritized the procurement of heparin, leading to supply chain disruptions and increased production efforts. However, the pandemic also strained manufacturing and distribution networks, resulting in occasional shortages. As the pandemic subsides, demand for Heparin Calcium is expected to stabilize, though its role in critical care remains pivotal.

The pharmacies segment is expected to be the largest during the forecast period

The pharmacies segment is estimated to have a lucrative growth, due to increased accessibility and distribution of this critical anticoagulant. As major pharmacy chains expand their reach, they ensure widespread availability of heparin calcium, especially in areas with high patient demand. These pharmacies play a pivotal role in making Heparin Calcium readily available to healthcare providers and patients, driving higher sales volumes. Additionally, large pharmacies often have the infrastructure to handle bulk purchasing and distribution, ensuring consistent supply, which supports market growth. Their influence in educating patients and healthcare providers further boosts the demand for Heparin Calcium in clinical settings.

The diagnostics segment is expected to have the highest CAGR during the forecast period

The diagnostics segment is anticipated to witness the highest CAGR growth during the forecast period, due to demand for this anticoagulant in various diagnostic and medical procedures, particularly in blood coagulation tests. Heparin Calcium is often used in laboratory testing to prevent blood clotting during sample collection, ensuring accurate results. Its role in diagnostic procedures, such as platelet aggregation and thrombin generation tests, is crucial for detecting clotting disorders. As diagnostic technologies advance, the need for high-quality, reliable anticoagulants like Heparin Calcium grows, further expanding its application in medical diagnostics and contributing to the market's growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period due to the raised prevalence of cardiovascular diseases, increasing surgical procedures, and an aging population. Countries like China, India, and Japan are key contributors, with expanding healthcare infrastructure and improved access to medical treatments driving demand. Moreover the market presents significant opportunities, especially in emerging economies where healthcare investments are increasing and the need for anticoagulants rises.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, due to growing aging population. The United States and Canada are key contributors, with robust healthcare systems and a high demand for anticoagulant therapies. Additionally, the presence of major pharmaceutical companies and advancements in medical research contribute to the market's growth. However, competition from newer, more convenient anticoagulants and the potential side effects of heparin calcium may pose challenges.

Key players in the market

Some of the key players profiled in the Heparin Calcium Market include Pfizer Inc., Sanofi S.A., B. Braun Melsungen AG, Baxter International Inc., Leo Pharma A/S, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals, Inc., Syntex S.A., Daiichi Sankyo Company, Limited, Nanjing King-friend Biochemical Pharmaceutical Co., Ltd., Bioiberica S.A.U., Xinbai Pharmaceuticals Co., Ltd., Laboratorios Rovi, S.A., Techdow Pharma and Opocrin S.p.A.

Key Developments:

In October 2024, Pfizer entered a multi-year collaboration with Tempus, a leader in AI and precision medicine, to leverage AI-driven insights in oncology therapeutic development. This partnership provides Pfizer access to Tempus's multimodal data library and AI capabilities, enhancing Pfizer's ability to accelerate oncology research and develop targeted treatments.

In October 2024, Baxter partnered with Oneview Healthcare to enhance connected care solutions in hospitals, focusing on improving workflows for nursing teams and patient experiences. This collaboration aims to integrate Oneview's Care Experience Platform (CXP) with Baxter's systems, creating a streamlined experience for patients and healthcare providers, especially in connected hospital rooms.

In April 2023, Sanofi acquired Provention Bio for $2.9 billion, a move to enhance its immunology pipeline. This acquisition strengthens Sanofi's position in treating immune-mediated diseases, adding promising therapies to its portfolio.

Products Covered:

Unfractionated Heparin
Low Molecular Weight Heparin (LMWH)
Other Products

Distribution Channels Covered:

Hospitals and Clinics
Pharmacies
Other Distribution Channels

Applications Covered:

Therapeutic Applications
Surgical Procedures
Diagnostics
Other Applications

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Heparin Calcium Market, By Product

5.1 Introduction
5.2 Unfractionated Heparin
5.3 Low Molecular Weight Heparin (LMWH)
5.4 Other Products

6 Global Heparin Calcium Market, By Distribution Channel

6.1 Introduction
6.2 Hospitals and Clinics
6.3 Pharmacies
6.4 Other Distribution Channels

7 Global Heparin Calcium Market, By Application

7.1 Introduction
7.2 Therapeutic Applications
- 7.2.1 Deep Vein Thrombosis (DVT)
- 7.2.2 Pulmonary Embolism (PE)
- 7.2.3 Myocardial Infarction (MI)
- 7.2.4 Atrial Fibrillation (AFib)
7.3 Surgical Procedures
- 7.3.1 Cardiovascular Surgery
- 7.3.2 Orthopedic Surgery
- 7.3.3 General Surgery
7.4 Diagnostics
7.5 Other Applications

8 Global Heparin Calcium Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 Pfizer Inc.
10.2 Sanofi S.A.
10.3 B. Braun Melsungen AG
10.4 Baxter International Inc.
10.5 Leo Pharma A/S
10.6 Fresenius SE & Co. KGaA
10.7 Teva Pharmaceutical Industries Ltd.
10.8 Hikma Pharmaceuticals PLC
10.9 Aspen Pharmacare Holdings Limited
10.10 Sagent Pharmaceuticals, Inc.
10.11 Syntex S.A.
10.12 Daiichi Sankyo Company, Limited
10.13 Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
10.14 Bioiberica S.A.U.
10.15 Xinbai Pharmaceuticals Co., Ltd.
10.16 Laboratorios Rovi, S.A.
10.17 Techdow Pharma
10.18 Opocrin S.p.A.

ヘパリンカルシウムの世界市場予測（～2030年）：製品、流通チャネル、用途、地域別の分析

Heparin Calcium Market Forecasts to 2030 - Global Analysis By Product (Unfractionated Heparin, Low Molecular Weight Heparin (LMWH) and Other Products), Distribution Channel, Application and By Geography

最大のシェアを占める地域

CAGRが最も高い地域：

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のヘパリンカルシウム市場：製品別

第6章 世界のヘパリンカルシウム市場：流通チャネル別

第7章 世界のヘパリンカルシウム市場：用途別

第8章 世界のヘパリンカルシウム市場：地域別

第9章 主な発展

第10章 企業プロファイリング